Tiziana Life Sciences PLC (NASDAQ: TLSA) announces that it has endorsed an agreement with FHI Clinical, a worldwide scientific contract research organization, to direct a Phase 2 Proof-of-concept revision in Brazil to assess the security, acceptability, and effectiveness of intranasal Foralumab in hospitalized patients with stark coronavirus illness 2019 (COVID-19) […]